Teva Donating More Than 10 Million Doses of Hydroxychloroquine as Potential COVID-19 Treatment

Teva Pharmaceutical (NYSE: TEVA) plans to donate 10 million tablets of the malaria drug hydroxychloroquine sulfate as a potential treatment for COVID-19. That news follows a report from earlier this week that Bayer (OTC: BAYRY) plans to donate 3 million tablets of the related drug chloroquine, which is more potent but has more hazardous side effects.